Pomalidomide
Genetic Condition
Intergroupe Francophone du MyelomeSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Genetic Condition cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Intergroupe Francophone du Myelome | Phase 3 | BB |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | B |
DEXAMETHASONE Quince Therapeutics S.p.A. | Phase 3 | B |
Nexiguran Ziclumeran Intellia Therapeutics | Phase 3 | B |
Zeleciment Rostudirsen Dyne Therapeutics | Phase 3 | B |
View all 16 →
Same molecule, other indications
Pomalidomide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →